Eradication treatment forPseudomonas aeruginosainfection in adults with bronchiectasis: a systematic review and meta-analysis
Open Access
- 31 January 2024
- journal article
- review article
- Published by European Respiratory Society (ERS) in European Respiratory Review
- Vol. 33 (171) , 230178
Abstract
Introduction: Pseudomonas aeruginosais the most commonly isolated pathogen in bronchiectasis and is associated with worse outcomes. Eradication treatment is recommended by guidelines, but the evidence base is limited. The expected success rate of eradication in clinical practice is not known.Methods: We conducted a systematic review and meta-analysis according to Meta-Analysis of Observational Studies in Epidemiology guidelines. PubMed, Embase, the Cochrane Database of Systematic Reviews andClinicaltrials.govwere searched for studies investigatingP. aeruginosaeradication treatment using antibiotics (systemic or inhaled) in patients with bronchiectasis. The primary outcome was the percentage of patients negative forP. aeruginosaat 12 months after eradication treatment. Cystic fibrosis was excluded.Results: Six observational studies including 289 patients were included in the meta-analysis. Our meta-analysis found a 12-monthP. aeruginosaeradication rate of 40% (95% CI 34–45%; p2=0%). Combined systemic and inhaled antibiotic treatment was associated with a higher eradication rate (48%, 95% CI 41–55%) than systemic antibiotics alone (27%, 13–45%).Conclusion: Eradication treatment in bronchiectasis results in eradication ofP. aeruginosafrom sputum in ∼40% of cases at 12 months. Combined systemic and inhaled antibiotics achieve higher eradication rates than systemic antibiotics alone.Keywords
This publication has 40 references indexed in Scilit:
- Eradication failure of newly acquired Pseudomonas aeruginosa isolates in cystic fibrosisJournal of Cystic Fibrosis, 2016
- Research priorities in bronchiectasis: a consensus statement from the EMBARC Clinical Research CollaborationEuropean Respiratory Journal, 2016
- Eradication Therapy against Pseudomonas aeruginosa in Non-Cystic Fibrosis BronchiectasisRespiration, 2015
- Management of bronchiectasis in adultsEuropean Respiratory Journal, 2015
- The Bronchiectasis Severity Index. An International Derivation and Validation StudyAmerican Journal of Respiratory and Critical Care Medicine, 2014
- Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trialThe Lancet, 2012
- Outcomes of Pseudomonas eradication therapy in patients with non-cystic fibrosis bronchiectasisRespiratory Medicine, 2012
- Comparative Efficacy and Safety of 4 Randomized Regimens to Treat EarlyPseudomonas aeruginosaInfection in Children With Cystic FibrosisArchives of Pediatrics & Adolescent Medicine, 2011
- Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trialThorax, 2009
- Factors Associated With Lung Function Decline in Adult Patients With Stable Non-Cystic Fibrosis BronchiectasisChest, 2007